Imigran

Sumatriptan, the active ingredient in Imigran, is a selective serotonin (5-HT1) receptor agonist presented as a tablet for oral use. It provides acute treatment of migraine attacks in adult patients by narrowing cranial blood vessels and inhibiting trigeminal pain pathways.

GNH USA supplies Imigran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imigran (sumatriptan) is used for the acute management of migraine and related headache disorders.

Migraine: rapid relief of headache pain and associated nausea or photophobia. Cluster headache: alleviation of pain during an acute cluster episode. Migraine with aura: reduction of aura severity and subsequent headache intensity.

Common and serious adverse reactions have been reported with sumatriptan use.

Common Side Effects: - Chest tightness or pressure - Tingling or numbness in fingers or face - Warmth or flushing sensation - Dizziness or light‑headedness - Nausea or mild stomach upset - Fatigue or drowsiness

Serious or Rare Side Effects: - Coronary vasospasm or myocardial infarction - Serotonin syndrome, especially with other serotonergic agents - Severe allergic reaction (anaphylaxis) - Sudden, severe hypertension - Stroke or transient ischemic attack

Before prescribing Imigran, clinicians should evaluate patient history and monitor for specific risk factors.

Assess cardiovascular history: confirm no uncontrolled coronary artery disease. Avoid in uncontrolled hypertension: monitor blood pressure before use. Contraindicated with MAO inhibitors: ensure appropriate washout period. Caution with other serotonergic drugs: watch for serotonin syndrome. Use lowest effective dose: titrate based on clinical response. Store at ambient temperature: keep in original pack, protect from moisture.

Sumatriptan may interact with several medication classes; careful assessment is required.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension. - Ergot alkaloids: additive vasoconstriction. - Other triptans: increased risk of cardiovascular events. - SSRIs, SNRIs, or other serotonergic agents: potential serotonin syndrome. - Strong CYP3A4 inhibitors (e.g., ketoconazole): elevated plasma levels.

Moderate Interactions (Monitor Closely): - Antihypertensives: possible additive blood pressure effects. - Non‑MAO antidepressants: monitor for serotonergic toxicity. - CYP2D6 inhibitors (e.g., fluoxetine): may increase exposure. - NSAIDs: heightened cardiovascular risk when combined.